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Purpose: To formulate biodegradable chitosan microspheres loaded with famotidine to overcome the 
poor bioavailability and frequent dose administration of the drug.  
Methods: Chitosan microspheres were prepared by simple emulsification technique based on 
glutaraldehyde crosslinking. Various process and formulation variables such as speed of emulsification, 
crosslinking time, drug/polymer ratio, volume of cross linking agent and volume of surfactant were 
optimized. The microspheres were characterized for entrapment efficiency, drug loading, in vitro drug 
release, surface morphology, as well as by particle size analysis, Fourier transform infrared (FTIR) 
spectroscopy and differential scanning calorimetry (DSC). 
Results: The microspheres showed a smooth surface with a narrow particle size distribution (105 – 219 
µm) and an entrapment efficiency of up to 73 %. They exhibited controlled drug release characteristics 
with 85.6 % of the drug released over a period of 24 h with an initial burst release of 26.9 % in the first 2 
h. Drug release followed Higuchi release kinetics. FTIR and DSC data indicate that there was no drug 
interaction between the drug and polymer used.  
Conclusion: The chitosan microspheres could be further developed as a potential biodegradable carrier 
for oral controlled delivery of famotidine. 
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INTRODUCTION 
 
Chitosan has wide industrial applications 
such as lubricant, disintegrant, thickening, 
stabilising and suspending agent in 
pharmaceutical, textile and paper industries 
[1]. It is also a chelating agent for the removal 
of harmful metals in industrial and nuclear 
wastes, and a support for ion exchange, 
chelation and affinity chromatography [2]. 
The principal industrial source of chitin is 
shells of shrimp, lobster and crab.  
 
Chitin and chitosan are distinguished by their 
solubility profile. Chitosan has favourable 
biological properties such as biodegradability, 
biocompatibility and non-toxicity. Chitosan 
was found to improve the fluidity of powder 
mixtures [3] and has satisfactory 
mucoadhesive property and good application 
potential [4]. Chitosan has antitumour activity, 
and hence chitosan microspheres bearing 
antineoplastic agents could be a promising 
carrier for cancer treatment [5]. It also holds 
immense promise for ophthalmic delivery [6].  
 
The pH-dependant solubility of chitosan is a 
function of the amino groups in the molecule 
and is a drawback for oral delivery in that 
chitosan microspheres formed by 
electrostatic interaction between a polyion 
and counterions become unstable in gastric 
fluid. This problem can be countered by 
irreversible chemical crosslinking. It has been 
demonstrated that drug diffusion from 
chitosan microspheres can be controlled by 
crosslinking with a dialdehyde such as 
glutaraldehyde [7]. 
 
Famotidine is a H2 receptor antagonist. It is 
widely prescribed in gastric and duodenal 
ulcers, Zollinger-Ellison syndrome and gastro 
esophageal reflux disease [8]. H2 receptor 
antagonists not only inhibit gastric secretion 
induced by histamine, gastrin and cholinergic 
stimulation, they also promote healing of 
duodenal ulcers [9]. H2 antihistamines, such 
as famotidine,  have achieved clinical 
success with regard to the indications 
highlighted above. They block more than 90 
% of nocturnal acid and 60 – 70 % of day-
time secretion. The relative potency of 
famotidine is also high when compared to 
other H2 –antihistamines. The recommended 
dose for duodenal, gastric ulcers, reflux 
esophagitis, NSAID ulcers and Zollinger-
Ellison syndrome is 20 – 40 mg twice daily. It 
has been reported that the oral treatment of 
gastric disorders with H2 antagonist, such as 
famotidine and ranitidine, when used in 
combination with antacids, promotes local 
delivery of these drugs to the receptor of 
parietal cell wall. Local delivery also 
increases stomach wall receptor site 
bioavailability and increases efficacy of drugs 
to reduce acid secretion. This principle may 
be applied for improving systemic as well as 
local delivery of famotidine, thereby efficiently 
reducing gastric acid secretion [10]. 
 
Based on the foregoing, it would be useful to 
develop a formulation that deliver famotidine 
to sites in the stomach and thus enhance the 
effectiveness of the drug as well as provide 
sustained action. Hence, the objective of this 
work was to develop biodegradable 
microspheres of famotidine using chitosan for 





Chitosan (mol wt, ca. 40 KDa) was supplied 
by Central Institute of Fisheries and 
Technology, Cochin, India while famotidine 
was obtained as a gift from Novartis, 
Bombay. Sorbitan sesquioleate, 
glutaraldehyde (25 %, aqueous), liquid 
paraffin (light, viscosity 18 cps), and 
petroleum ether were obtained from Loba 
Chemie Pvt Ltd, Bombay. All the other 
chemicals used were of analytical grade. 
 
Preparation of famotidine-loaded chitosan 
microspheres 
 
Famotidine-containing chitosan microspheres 
were prepared at various drug: polymer ratios 
using a simple emulsion technique. A gel (6g) 
was prepared using chitosan (4 %) in 5 % 
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aqueous acetic acid containing 2 % NaCl and 
the drug was added to it in varying 
drug:polymer ratios. The mixture was 
dispersed in a mixture of 35 ml liquid paraffin 
and 25 ml of petroleum ether containing 0.85 
g of sorbitan sesquioleate in a 100 ml round 
bottom flask at room temperature [11]. The 
dispersion was stirred using stainless steel 
half moon-shaped paddle stirrer at 2000 rpm 
for 5 min and then 10ml of glutaraldehyde 
saturated toluene (GST), prepared according 
to the method of Patel et al [12],  was 
introduced into the flask while stirring. At the 
end of 30 min, glutaraldehyde (25 %v/v, 
aqueous) was added and stirring continued. 
In preliminary trial batches, the volume of the 
crosslinking agent (glutaraldehyde saturated 
in toluene) and crosslinking time were varied 
from 0.5 – 15 ml and 1 - 3 h, respectively. 
The stirrer speed was also varied from 1500 
– 3000 rpm. Stirring was continued  for a total 
duration of 90min, at the end of which the 
hardened microspheres were filtered, washed 
several times, first with petroleum, then with 
acetone, 5% solution of sodium 
metabisulphate, and finally with water. The 
microspheres thus obtained were dried 
overnight in oven at 60 ºC and stored in a 
desiccator. 
 
Determination of loading efficiency 
 
Famotidine drug content in the preparation 
was determined by extracting the drug from 
the microspheres with 0.1M HCl. In this 
method, the microspheres (50 mg) were 
stirred in 50ml of 0.1M HCl until dissolved; it 
was filtered through a Millipore filter and the 
drug content determined, after suitable 
dilution, at 265 nm by spectrophotometry 
(Perkin Elmer- Lambda 25). The loading 
efficiency (L) of the microspheres was 
calculated according to Eq 1 [13]. 
 
L (%) = (Qm /Wm) x 100 …………..……… (1) 
 
where Wm is the  weight of the microspheres 
and Qm  is the amount of drug present in of 




Fifty milligrams of accurately weighed 
microspheres were crushed in a glass mortar 
with a pestle and suspended in 10 ml of 0.1M 
HCl at pH 2. Twenty four hours later, the 
solution was filtered and the filtrate analysed 
for drug content as described for loading 
efficiency. Drug entrapment (E) was 
calculated using Eq 2 [12]. 
 
E (%) = W/T x 100 ………………………… (2) 
 
where W is the actual drug content of the 
microspheres while T is the theoretical 
content of the drug. 
 
Particle size analysis and characterization 
of surface morphology 
 
The size distribution of the microspheres in 
terms of their average diameter (davg) was 
determined by optical microscopy (CosLab). 
Scanning electron microscopy (SEM, 
Hitachi S-520) was performed to characterize 
the surface morphology of the microspheres. 
was All determinations were carried out in 
triplicate.  
 
Fourier transform infrared (FT-IR) 
spectroscopy  
 
FT-IR spectra of chitosan, famotidine and 
drug-loaded microspheres were recorded on 
a PerkinElmer (Spectrum R-X1) instrument 
using KBr disc in the range of 4000 – 400 cm
-
1
 in order to assess structural changes that 
could have occurred in the drug or polymer 
as a result of microsphere formulation. 
 
Differential scanning calorimetry (DSC) 
 
As DSC is a useful tool to monitor the effect 
of additives on the structural behavior of a 
material, this technique was used to obtain 
information about the physicochemical 
interaction the microsphere material and the 
drug [14]. Differential scanning calorimetry 
(DSC) of famotidine, blank microspheres, and 
drug loaded microspheres was performed 
with a DSC facility (model 821e, Mettler 
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Toledo). Measurements were performed over 
a temperature range of 20 to 240 ºC at a 
heating rate of 10 ºC/min. 
 
In vitro release study 
 
In vitro release study on the microspheres 
(50 mg) was carried out in 50 ml of 0.1M HCl 
(pH 2) in a bottle at 37 ºC for the first two 
hours to simulate gastric conditions, and then 
in 50 ml of phosphate buffer (pH 6.8). The 
bottle was clamped in the orbital shaker 
(Remi) and agitated at 50 rpm. Samples 
(5ml) were collected at predetermined time 
intervals, for up to 24 h, for analysis. The 
medium was replenished with an equal 
volume of the dissolution medium after each 
sampling. The samples were analysed with a 
UV spectrophotometer (Perkin Elmer –
Lambda 25) at 265 nm. All determinations 




Statistical analysis was performed with Graph 
Pad Instat 3 software. All the tests were run 
in triplicate (n = 3). Experimental results were 
expressed as mean ± SD, and analyzed by 
one-way ANOVA for drug release data. 




Preparation of microspheres 
 
Following preliminary trials, 10 ml of 
glutaraldehyde saturated in toluene (GST), 
stirring speed of 2000 rpm and crosslinking 
time of 3h were adopted as processing 
factors for the preparation of the 
microspheres evaluated in this work. 
 
Drug-loading and entrapment efficiency 
 
Table 1 shows that drug loading efficiency 
increased with increasing in the proportion of 
the polymer relative to the drug. Variation in 
drug : polymer ratio from 1:1 to 1:3 produced 
a drug loading efficiency of 15 ± 2 and 23 ± 3 
% w/w. Further increase in polymer 
concentration showed slight reduction in the 
drug loading efficiency. (Table 1) 
 
Similarly, the entrapment efficiency of the 
microspheres also increased with increase in 
the proportion of the polymer relative to the 
drug, giving entrapment values of 30 ± 3 % 
w/w to 75 ± 5 %w/w for drug polymer ratios of 
1:1 and 1:4, respectively. However, further 
increase in the proportion of the polymer 
resulted in a decrease in entrapment 
efficiency.    
 
Particle size  
 
As Table 1 shows, the mean particle size 
(diameter) of the microspheres increased 
with increase in the proportion of polymer 
relative to that of drug, with 42 % of the 
particles below 75 µm, 35 % in the range 75 - 
150 µm and 33 % in the range 150 – 300 µm. 
When the stirring speed was lowered to 1500 
rpm, the proportion of large microspheres 
(150 – 300 µm range) increased. On the 
other hand, increase in stirring speed beyond 
3000 rpm lowered particle size. 
 
Scanning electron microscopy  
 
The SEMs of the microspheres in Fig 1 
indicate that they were fairly smooth and 
spherical in shape with an apparently 





Fig 1: Scanning electron micrographs of 
famotidine-loaded chitosan microspheres with 





Ramachandran et al  
Trop J Pharm Res, June 2011;10 (3): 313 
A 










F1 1:1 105±12 15±2 30±3 
F2 1:2 130±15 18±3 55±5 
F3 1:3 195±14 23±3 73±7 
F4 1:4 207±13 21±2 74±5 




The FTIR spectra of chitosan, famotidine and 
famotidine-loaded chitosan microspheres are 
shown in Fig 2. The FTIR spectrum of 
chitosan depict a characteristic absorption 
band at 3437 cm
-1
 representing the presence 
of a hydrogen bonded OH group. The amino 
group showed a characteristic absorption 
band in the region of 3400 - 3500 cm
-1 
which 
must have been masked by an O-H group 
absorption band. The polymer also showed 
the characteristic bands of amide at 1654, 
1608 and 1323 cm
-1
. The ether linkage 





The spectrum of famotidine showed an NH 
group (amine) characteristic absorption band 
at 3505 cm
-1
 as well as characteristic 
sulfonamide bands at 3400, 1350 and 1180 
cm
-1
. The absorption band at 1650 cm
-1
 
represents >C=N-H group while the 
methylene rocking vibration of C-H bond 





The spectrum of famotidine-loaded 
microspheres showed absorption bands at 
2854, 1458 and 1367 cm
-1
, reflective of the 
glutaraldehyde-crosslinked chitosan. The 
bands were rather intense as a consequence 
of aliphatic C-H absorption. The new sharp 
peak at 1610 cm
-1
 represents stretching 
vibrations of C=N in Schiff’s base formed by 
the reaction of glutaraldehyde and chitosan. 
The presence of S=O band at 3420 cm
-1
 , 
ether linkage at 1100 cm
-1
 and amide band at 
1698 and 1500 cm
-1
 proves that there was no 





Fig 2: FTIR spectra of (A) chitosan microspheres, 
(B) famotidine, and (C) famotidine-loaded chitosan 
microspheres. 
 
Differential scanning calorimetry (DSC) 
 
The thermograms of chitosan, famotidine 
drug and famotidine loaded chitosan 
microspheres are shown in Fig 3. The 
thermogram of chitosan showed a broad 
peak at 58 ºC which is attributed to water loss 
due to evaporation of absorbed water. No 
degradation DSC was observed for chitosan 
which would normally have occurred at 280 
ºC [15,16]. Famotidine thermogram showed a 
sharp endothermic peak at 158 ºC which 
corresponds to its melting point which is 
usually in the range 157-160 ºC. This peak 
was absent in the thermogram for the drug-
loaded chitosan microspheres. 
 
In vitro release  
 
The drug release data for the microspheres 
are shown in Fig 4. Cumulative drug release 
was 58.9, 76.0, 85.6, 84.6 and 70.3 %, 
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drug/polymer (D/P) ratio at the end of 24 h. 
Te batch with a D/P ratio of 1:3 showed the 
highest initial rapid or burst release of 26.9 % 
in 2 h as well as the highest cumulative drug 




Fig 3: DSC thermograms of (a) chitosan, (b) 
famotidine, and (c) famotidine-loaded chitosan 
microspheres  
 
On subjecting the drug release data to the 




in order to ascertain 
the drug release mechanism, a linear 
relationship was observed with a regression 



















Fig 4: Famotidine release from chitosan 
microspheres (♦ = F1 (1;1), □ = F2 (1;2), ∆ = F3 





Chitosan was selected as a polymer for the 
preparation of microspheres owing to its 
biodegradable, antiulcer, mucoadhesive 
properties as well as the possibility that it 
may offer synergism in the treatment of ulcer.  
 
Famotidine microsphere production method 
was premised partly on the poor solubility of 
chitosan in water. Addition of acid improves 
the polymer’s solubility as a result of the 
protonation of the amino groups. Its solubility 
is also dependent on other anions present in 
the solution. In the presence of acetate, 
lactate or glutamate, chitosan shows good 
solubility while phosphate, polyphosphate, 
sulphate and glutaraldehyde decrease its 
solubility [17]. For this reason, acetic acid 
was selected to dissolve the chitosan and 
glutaraldehyde was used for microsphere 
formation. Use of glutaraldehyde leads to the 
formation of a poorly soluble chitosan 
derivative which makes microsphere 
formulation become possible [11]. 
 
Drug release  
 
When the volume of glutaraldehyde used in 
the microsphere preparation was increased 
to 15 ml, drug release decreased. This is 
because increase in glutaraldehyde 
concentration yielded highly crosslinked 
spheres with high density and reduced 
diffusion pathways. Increase in stirring speed 
beyond 3000 rpm has decreased particle size 
to as small as 10 µm thus resulting in faster 
drug release due to the increased surface 
area in contact with the dissolution medium. 
Increase in the crosslinking time favoured 
controlled release of drug from the 
microspheres. This is also due to the 
hardening of the spheres as a result of longer 
crosslinking time.  
 
Drug-loading and entrapment efficiency 
 
Several factors affect the entrapment 
efficiency of drugs in chitosan microspheres, 
e.g., nature of drug, chitosan concentration, 
drug polymer ratio, stirring speed, etc [18], At 
higher polymer concentrations, chitosan 
forms a highly viscous solution which is very 
difficult to process.   
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The increase in drug-loading and entrapment 
efficiency with increase in the polymer 
content of the microspheres can be attributed 
to the fact that at higher polymer 
concentrations, chitosan viscosity leading to 
a less diffuse matrix structure that hinders 
drug escape from the microsphere core. 
However, excessively high plymer content 
would hinder homogeneous distribution of the 
added crosslinking agent (glutaraldehyde) 
leading to the formation of larger particles 





Mean particle size increased with increase in 
polymer content of the microspheres. It 
seems that when polymer content increased, 
a more viscous internal phase manifested 
during the emulsification process, and was 
poorly dispersed in the external phase.  The 




FTIR and DSC results obtained indicate that 
there were no interactions between 
famotidine, chitosan and the other ingredients 
used in the formulation, thus suggesting that 
the formulations would be stable. The 
absence of thermogram for the drug in the 
drug-loaded microsphere indicates that the 
drug was molecularly dispersed in the 
polymer matrix as a solid solution. 
 
Optimum famotidine formulation 
 
The in vitro release profiles of F1, F2 and F3 
depended mainly on drug entrapment 
efficiency. Although the polymer content of 
F3 was relatively high, it also showed a high 
cumulative drug release due to its high drug 
entrapment. Thereby the increase in drug 
release was in the order of F1< F2< F3. 
While drug entrapment in F4 was higher than 
in F3, it, however, showed lower drug release 
due to its higher polymer concentration. In F5 
both lower entrapment efficiency and higher 
polymer concentration and these might have 
led to a marked reduction in drug release. 
Thus, F3 (drug polymer ratio, 1:3) with a 
rapid burst release of 26.9 % in 2 h (due 
probably to a relatively high amount of drug 
entrapped near the surface of the 
microsphere) [19], and overall (sustained) 
release of 85.6 % in 24 h that fitted well into 
Higuchi kinetic release model, can be 
considered, amongst all the formulations 
evaluated, to be the most suitable formulation 
in terms of reduction in frequency of 
administration of famotidine microsphere 
formulation and, thus has the potential to 




The famotidine formulations developed in this 
study showed some potential for controlled 
delivery of famotidine and hence improved 
patient compliance. However, it would be 
necessary to undertake further studies, 
including bioavailability, in animal models 
with a view to determining if there is in vitro - 
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